NOMOCAN1
NOOMO1
NOOMOCAN15
 

ABOUT US

NomoCan Pharmaceuticals offers first-in-kind targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, 
it introduces a highly effective monoclonal antibody (mAb) drugs for the treatment of various cancers in order to 
“Bring Hope” to patients affected by this devastating disease.​
 ​Pancreatic Cancer is one of the most aggressive cancers
with a 5-year survival of 8%. NomoCan’s NMC-001 is a selective and specific monoclonal antibody that is the first in its kind to be developed for pancreatic cancer. NomoCan’s NMC-001 effectively targets cancer cells without harming normal cells and therefore will not have the side effects of non-specific chemotherapeutic agents currently in the clinic. 

Bring Hope

PIPELINE

NMC-001

NMC-001 monoclonal antibody targets a specific pancreatic cancer marker and is able to selectively identify and diagnose pancreatic cancer in human. With a high affinity for its target, NMC-001 demonstrates potent anti-tumor efficiency in rodent models of pancreatic cancer. 

53,670

New Cases of

Pancreatic Cancer

diagnosed in 2017

43,090

Estimated Deaths of

Pancreatic Cancer

in 2017

8.2%

5-Year Survival 

 
 

TEAM

Ehsan S. Yazdi, Ph.D., M.P.H.

Co-Founder & Chief Executive Officer

Victor Adler, M.D., Ph.D.

Chief Scientific Officer

Owen O'Connor, M.D., Ph.D.

Board of Directors , Member 

Kamyar Neshvadian, M.S., F.R.M.

Co-Founder & Chief Financial Officer

Lei Zhang, M.D.

Chief Clinical & Regulatory Officer

Jean Paul Thiery, Ph.D.

Chief Scientific Advisor 

Jahanara Ali, Ph.D.

Chief Business Development Officer

Mark Junewicz, M.B.A

Senior Financial Advisor

 
 

CONTACT

For more information, please contact us below.
Our Address

NomoCan Pharmaceuticals LLC

310 E 67th Street, Suite 1-45

New York, NY 10065

© 2017 NomoCan All Rights Reserved.